Stay updated on SL-401 Combo in AML/MDS/BPDCN Clinical Trial
Sign up to get notified when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.

Latest updates to the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page adds a note that PubMed publications are auto-filled and may not be about the study, and updates the revision label from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved a site-wide notice about a lapse in government funding and NIH operating status from this page, and the study details, eligibility criteria, and other essential content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check35 days agoChange DetectedThe study contact section was updated to include a backup contact (Veronica Zehnder) with email and phone, and old contact details were removed.SummaryDifference0.9%

- Check42 days agoChange DetectedNo significant changes detected; the observed differences are minor UI/formatting updates that do not affect the study's core information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange DetectedVersion updated to v3.2.0 with a government funding notice; removal of the term 'CD4+/CD56+ hematodermic neoplasm' from the content.SummaryDifference3%

- Check78 days agoChange DetectedAdded new contact details and updated version to v3.1.0, replacing the previous v3.0.2.SummaryDifference0.1%

Stay in the know with updates to SL-401 Combo in AML/MDS/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.